Eye Allergy Treatment Market Trends

Global Eye Allergy Treatment Market Overview

The Eye Allergy Treatment Market was valued at USD 3.35 billion in 2023. The industry is projected to grow from USD 3.55 billion in 2024 to USD 5.62 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.23% during the forecast period (2024 - 2032). The rising prevalence of eye allergy and expanding geriatric population and Surging drug launches in order to meet high demands are driving the market growth.

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Victor Reinz Reinzosil Room-Temperature Vulcanizing (RTV) Silicone, a sealing technology provider that is well-known in the industry, introduced its product in October 2021 in North America. Reinzosil is a silicone-based sealer that exhibits outstanding resistance to various types of liquids and extreme temperatures. It is a quick-drying sealant and an easy-to-use one with high durability to cure quickly. It has good bonding properties even on rough surfaces and it also remains stable even at higher temperature changes.

Bostik announced its latest range of polyurethane sealants for the construction industry, which will be available from July 2021. The world-class adhesive manufacturer Bostik is committed to develop an extensive range of elastomeric sealants with enhanced technical features and superior performance, including solvent-free formulation, low levels of isocyanates, ease of application, and bubble-free manufacture within large-scale production sites across Asia Pacific & Europe using cutting edge technologies hoping to strengthen its position in construction sectors primarily emerging markets.

This new range of silicone-based elastomeric sealants for construction applications was recently launched by BASF SE, referred as MasterSeal 9500, in 2021. This product has been designed to withstand long-term exposure to weathering elements, thereby making it ideal for use under harsh conditions.

3M introduced another line called “3M Fire and Water Barrier Sealant” earlier this year (2021). Because it resists fire and water over time, this item makes it very useful in residential or commercial places.

H.B. Fuller Company bought Brazil’s producer of adhesive technologies such as elastomeric sealants – Adecol Indústria Química, located in São Paulo in 2020; As per reports, the deal was aimed at expanding H.B.Fuller’s product portfolio while strengthening its position in South American market.

Eye Allergy Treatment Market Trends

• Rising Prevalence of Eye Allergy and Expanding Geriatric Population

The increasing prevalence of eye allergies across the world is burgeoning the growth of the Eye Allergy Treatment Market. For instance, in February 2020, Alcon, a Novartis AG (US) company, reported that there were nearly 66 million Americans suffering from eye allergies. Moreover, the increasing geriatric population is also fueling the growth of the eye allergy treatment market. For instance, as per Senior Home Plus (UK), eye allergies in the elderly population occur due to a weakened immune system, chronic health conditions, reduced tear production, and some medication side effects that have been prescribed to the elderly population. market for significant growth. For instance, according to the World Population Prospects 2022, the population over the age of 65 is growing faster than the population under that age. Moreover, it has been estimated that that the proportion of the global population aged 65 and up was expected to rise from 10% in 2022 to 16% by 2050. Furthermore, the increasing geriatric population in Asia-Pacific will create lucrative growth opportunities in upcoming years. As per the Asia-Pacific Report on Population Ageing 2022, there were approximately 670 million people aged 60 or older in Asia-Pacific in 2022. Thus, the increasing prevalence of eye allergies and the growing geriatric population are burgeoning the growth of the global market.

The eye allergy treatment market is expanding rapidly, fuelled by new drug launches aimed at meeting high demand. With an increasing global prevalence of eye allergies, there is a greater demand for effective and innovative treatment options. For instance, in September 2020, Dr. Reddy's Laboratories (India) launched an over the counter (OTC) eye allergy drop, namely olopatadine hydrochloride ophthalmic solution, in the US market. This solution is indicated for the temporary relief of itchy eyes due to pollen, ragweed, animal hair, dander, and grass. Furthermore, in February 2020, Alcon (Switzerland) company, launched Pataday, an eye allergy drop that contains olopatadine hydrochloride ophthalmic solution. The Pataday brand features the No. 1 doctor-prescribed eye allergy itch relief ingredient as well as the first once-daily allergy itch relief drop available without a prescription. As a result, the eye allergy treatment market is rapidly expanding, with opportunities for further growth as companies address patients' evolving needs.

Eye Allergy Treatment Market Segment Insights

Eye Allergy Treatment Type Insight

Based on type, the Eye Allergy Treatment Market has been segmented into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, and giant papillary conjunctivitis. The seasonal and perennial allergic conjunctivitis segment dominated the market in 2023, while the atopic keratoconjunctivitis segment is projected to be the fastest-growing segment during the forecast period, 2024-2032.  

Seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) are among the most common forms of eye allergies worldwide. They are triggered by allergens such as pollen, dust mites, and animal dander, affecting a large population during specific seasons or year-round. There are well-established treatment options for Seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC), including antihistamine eye drops, mast cell stabilizers, corticosteroids, and combination therapies. These treatments effectively alleviate symptoms and manage allergic reactions, contributing to the segment's market dominance.

Figure 2: EYE ALLERGY TREATMENT MARKET SIZE, BY TYPE, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Eye Allergy Treatment Drug Class Insights

Based on drug class, the Eye Allergy Treatment Market is segmented into antihistamine, mast cell stabilizer, NSAIDS, corticosteroid, decongestants, immunotherapy allergy shots, and others. The antihistamine segment dominated the market in 2023, while the immunotherapy allergy shots segment is projected to be the fastest-growing segment during the forecast period, 2024-2032.

Antihistamines are widely recognized for their ability to block histamine receptors, which are responsible for allergic reactions such as itching, redness, and swelling of the eyes. They provide rapid relief from allergy symptoms. Patients often prefer antihistamines due to their established efficacy, rapid onset of action, and minimal systemic side effects compared to other drug classes. Antihistamines have been fundamental in allergy treatment for many years, with extensive clinical research supporting their efficacy and safety. This strong foundation of evidence built a confidence in healthcare providers and patients alike, contributing to their ongoing dominance in eye allergy treatment market.

Eye Allergy Treatment, by Treatment Form Insights

Based on treatment form, the Eye Allergy Treatment Market is segmented into eyedrops, injectables, and tablets & capsules. The eyedrops segment dominated the market in 2023, while the injectables segment is projected to be the fastest-growing segment during the forecast period, 2024-2032.

Eyedrops are specifically formulated for direct application to the eyes, allowing for targeted delivery of medications to relieve symptoms such as itching, redness, and irritation associated with eye allergies. This direct application provides rapid relief and is convenient for patients. They are generally easy to administer and can be used multiple times a day as needed. Patients appreciate the simplicity and non-invasive nature of eyedrop treatments compared to injectables or oral medications. Many eyedrop formulations for mild to moderate eye allergies are available over the counter (OTC), making them easily accessible without requiring a prescription. This accessibility contributes to their widespread use and market dominance.

Eye Allergy Treatment Distribution Channel Insights

Based on distribution channel, the Eye Allergy Treatment Market is segmented into hospital pharmacies, online pharmacy, and retail pharmacy. The hospital pharmacies segment dominated the market in 2023, while the retail pharmacy segment is projected to be the fastest-growing segment during the forecast period, 2024–2032.

Hospital pharmacies ensure immediate access to a wide range of medications required for treating severe or acute eye allergies. This includes injectables, specialized eye drops, and medications that may not be readily available in retail pharmacies or online. For patients experiencing severe allergic reactions affecting the eyes, hospital pharmacies offer emergency care and critical support. Therefore, Hospital pharmacies play a pivotal role in the eye allergy treatment market due to their capacity to deliver specialized care, prompt access to medications, emergency readiness, strict adherence to regulatory standards, and seamless integration into healthcare systems. These elements combine to establish their dominance in effectively managing and treating diverse types of eye allergies.

Eye Allergy Treatment Regional Insights

Based on region, the Eye Allergy Treatment Market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest market share in 2023 and is anticipated to reach USD 1.94 billion by 2032, registering a CAGR of 4.29% during the forecast period. However, Asia-Pacific is projected to grow at the highest CAGR of 7.11% during the forecast period.

The growth of the Americas is due to its rising geriatric population and increasing ophthalmological disorders, causing an increased need for diagnosis and therapeutics. in February 2020, Alcon, a Novartis AG (US) company, reported that there were nearly 66 million Americans suffering from eye allergies. This huge prevalence of eye allergies is driving the growth of the eye allergy treatment market.

Americas region is followed by Europe, which accounted for the second largest eye allergy treatment market share owing to the rising patient population with eye disorders, availability of advanced treatment facilities, increasing healthcare expenditure, and the introduction of advanced therapies into the market along with the presence of good healthcare infrastructure. Additionally, rising government initiatives are driving the growth of the market. Moreover, the increasing geriatric population is also fueling the growth of the eye allergy treatment market. For instance, as per Senior Home Plus (UK), eye allergies in the elderly population occur due to a weakened immune system, chronic health conditions, reduced tear production, and some medication side effects that have been prescribed to the elderly population. market for significant growth.

Asia-Pacific is the fastest-growing market for the Eye Allergy Treatment Market. The presence of a huge patient population, rapid development in technology, and the presence of huge opportunities for the development of the market drive the growth of the eye allergy treatment market in Asia-Pacific. Additionally, the rising elderly population is also fueling the market of eye allergy treatments in this region.  As per the Asia-Pacific Report on Population Ageing 2022, there were approximately 670 million people aged 60 or older in Asia-Pacific in 2022. Thus, the increasing prevalence of eye allergies and the growing geriatric population are burgeoning the growth of the global market.

Figure 3: EYE ALLERGY TREATMENT MARKET BY REGION 2023 & 2032 (USD Billion)

Global Eye Allergy Treatment Key Market Players & Competitive Insights

The Eye Allergy Treatment Market is distinguished by the presence of numerous global, regional, and local players catering to eye allergy treatment medications. Furthermore, the rising prevalence of eye allergy and expanding geriatric population and surging drug launches to meet high demand is further driving the growth of Eye Allergy Treatment Market during the forecast period. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their products and signing contracts and agreements to broaden their reach. For instance, in February 2021, Bausch + Lomb (Canada) Launched Alaway preservative free antihistamine eye drops.  This medication is used to prevent and treat itching of the eyes caused by allergies (allergic/seasonal conjunctivitis).

The Eye Allergy Treatment Market is extremely competitive, with players competing, partnering, and investing heavily in research and development to gain a significant market share. The market is moderately fragmented with rising competition, increasing collaborative partnerships, and other strategic decisions to achieve operational efficiency.

Mergers and collaborations were also observed to expand the company's product portfolio, as well as introduce new eye allergy treatment medications. The growth of prominent industry players is dependent on various factors, such as market conditions, government support, and industry development. It is also projected that a rise in the investments for R&D will also boost the market's growth in the upcoming future.

Major players in the Eye Allergy Treatment Market, including Johnson & Johnson Services, Inc, Abbvie Inc., Sun Pharmaceutical Industries ltd., Teva Pharmaceutical Industries Ltd, Hal Allergy B.V., Novartis AG, Bausch + Lomb, and others, are making investments in R&D activities to boost market demand.

Santen Pharmaceutical Co., ltd. is a manufacturer of ophthalmic drugs. The company produces a wide range of products, including eye drops and ointments. It provides both over the counter and prescription ophthalmic products for conditions like bacterial conjunctivitis, dry eye, inflammation, cataracts, muscae volitantes, diabetic retinopathy, retinal detachment, hypophagia, amblyopia, astigmatism, strabismus, hordeolum, and VDT syndrome Furthermore, it has manufacturing plants in Noto, Shiga, and Suzhou, Japan, as well as Suzhou, China. Santen's headquarters are in Kita-Ku, Osaka, Japan.

Moreover, In June 2021, Santen Pharmaceutical Co., ltd receives U.S. FDA Approval for Verkazia (Cyclosporine ophthalmic emulsion, 0.1%) for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.

Key Companies in the Eye Allergy Treatment Market include.

• Johnson & Johnson Services, Inc.


• Abbvie Inc.


• Sun Pharmaceutical Industries Ltd.


• Teva Pharmaceutical Industries Ltd.


• Hal Allergy B.V.


• Novartis AG


• Bausch + Lomb


• Santen Pharmaceutical Co., ltd.


• Alcon


• Bayer AG

Global Eye Allergy Treatment Industry Developments

June 2021: Santen Pharmaceutical Co., ltd receives U.S. FDA Approval for Verkazia (Cyclosporine ophthalmic emulsion, 0.1%) for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.

May 2021: Teva Pharmaceuticals (Israel) has announced the launch of generic Erythromycin tablets in 250 mg and 500 mg strengths, which are therapeutic equivalents of Arbor Pharmaceuticals' reference listed drug (RLD) Erythromycin Tablets.

February 2021: Bausch + Lomb (Canada) Launched Alaway Preservative Free Antihistamine Eye Drops.  This medication is used to prevent and treat itching of the eyes caused by allergies (allergic/seasonal conjunctivitis)

May 2020: The US Food and Drug Administration (FDA) has approved Alcon's Pataday eye allergy scratch drop. Pataday Ophthalmic Solution belongs to the class of medications called antihistamines. It is used to treat seasonal allergic conjunctivitis, an allergic reaction caused by fur, dust, pollen, and other allergens that cause an eye infection, redness, inflammation, and swelling.

November 2019: Santen Pharmaceutical Co. Ltd (Japan) launched an anti-allergic ophthalmic solution Alesion LX Ophthalmic Solution 0.1% in Japan.  This medicine suppresses allergic symptoms such as itchy/bloodshot eyes by histamine H1-receptor antagonism and suppressing the release of allergy-causing substances such as histamine. In most cases, allergic conjunctivitis is treated with it.

October 2019: Sun Pharmaceutical Industries Ltd.'s (India) wholly owned subsidiary has launched CEQUA (cyclosporine ophthalmic solution) 0.09% in the United States. CEQUA, the FDA-approved highest dosage of cyclosporine for ocular usage, can boost tear production in patients with keratoconjunctivitis sicca.

Eye Allergy Treatment Market Segmentation

Eye Allergy Treatment Type Outlook

• Seasonal and Perennial Allergic Conjunctivitis


• Vernal Keratoconjunctivitis


• Atopic Keratoconjunctivitis


• Contact Allergic Conjunctivitis


• Giant Papillary Conjunctivitis

Eye Allergy Treatment Drug Class Outlook

• Antihistamine


• Mast Cell Stabilizer


• NASAIDs, Corticosteroid


• Decongestants


• Immunotherapy Allergy Shots


• Others

Eye Allergy Treatment Form Outlook

• Eyedrops


• Injectables


• Tablets & Capsules

Eye Allergy Treatment Distribution Channel Outlook

• Hospital Pharmacy


• Online Pharmacy


• Retail Pharmacy

Eye Allergy Treatment Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America